Compound Reference

Semaglutide

GLP-1 receptor agonist · the incretin class · marketed as Ozempic / Wegovy / Rybelsus

Metabolic · incretin (GLP-1) Evidence: large Phase 3 RCTs FDA-approved drug

Important distinction. Semaglutide is an FDA-approved prescription drug — a different category from research-use-only peptides. This page is educational science, not medical advice, and not an endorsement of obtaining it outside a licensed prescription. "Research"/compounded semaglutide sold as a chemical is a separate, riskier thing (see Regulatory below).

The discovery — why GLP-1 matters

In the 1980s, Svetlana Mojsov (working in Rockefeller's peptide-synthesis tradition founded by Bruce Merrifield) synthesized glucagon-family analogs and identified the truly bioactive incretin fragment, GLP-1(7-37) — the 31-amino-acid sequence that actually stimulates insulin.¹ That single identification underpins the entire GLP-1 drug class and earned a 2024 Lasker~DeBakey Award. Semaglutide is an engineered descendant of that native peptide.

Mechanism of action

Semaglutide is a GLP-1 receptor agonist. The GLP-1 receptor is a class B G-protein-coupled receptor (GPCR) — the receptor family whose structural biology Stanford's Brian Kobilka won the 2012 Nobel for, and the target of a large share of all drugs.² Activating it produces the "incretin effect":

Glucose-dependent insulin secretion — it prompts the pancreas to release insulin only when blood glucose is elevated, which is why it rarely causes hypoglycemia on its own.
Glucagon suppression — lowers the hormone that raises blood sugar.
Slowed gastric emptying — food leaves the stomach more slowly.
Central appetite/satiety signaling — acts on hypothalamic circuits to reduce hunger, the main driver of weight loss.

Half-life engineering — the key teaching point

Native GLP-1 is almost useless as a drug: enzyme DPP-4 chops it up and its half-life is roughly 2 minutes. The engineering story of the whole class is how you make a 2-minute peptide last a week:

The trick: semaglutide adds a C18 diacid fatty-acid chain via a linker (lipidation/acylation). That chain lets the molecule bind reversibly to albumin in the blood, hiding it from clearance and DPP-4. The result: a half-life of about 165 hours — a ~5,000× extension that enables once-weekly dosing. Two amino-acid substitutions further resist DPP-4.³

This is the same toolkit — lipidation, albumin-hitchhiking, PEGylation, DAC linkers — used across modern long-acting peptides. Understanding it explains why "No-DAC" vs "DAC" versions of other peptides behave so differently.

Class	GLP-1 receptor agonist (incretin mimetic)
Parent peptide	GLP-1(7-37), 31 aa (Mojsov)
Key modification	C18 diacid acylation + linker (albumin binding) + DPP-4-resistant substitutions
Half-life	≈ 165 h (once-weekly) — vs ≈ 2 min for native GLP-1
Receptor	GLP-1R, a class B GPCR

State of the evidence

Unlike RUO peptides, semaglutide has one of the largest modern trial bases of any drug: the SUSTAIN program (type 2 diabetes), the STEP program (obesity), and cardiovascular-outcomes trials such as SELECT. This is why it's FDA-approved — the evidence tier here is "large Phase 3 RCTs + outcomes data," the opposite end of the spectrum from a compound like BPC-157 (zero Phase III). Known trade-offs include GI side effects (nausea, etc.) and active research into muscle-mass and long-term questions.

Regulatory reality — the compounding wrinkle

Approved product: semaglutide is FDA-approved (Ozempic/Wegovy/Rybelsus) and prescription-only.
Compounded "research" semaglutide: during the shortage, compounded versions proliferated. That window has closed — the FDA has moved to exclude semaglutide (and tirzepatide, liraglutide) from the 503B bulks list, and "essentially a copy" compounding is impermissible now that supply has stabilized.⁴ Powder sold as a research chemical is neither the approved drug nor a legal medicine.

Open questions

Long-term durability, muscle preservation, and what happens on discontinuation.
How next-gen dual/triple agonists (tirzepatide, retatrutide) compare on efficacy and tolerability.
Emerging non-metabolic effects (cardiovascular, neurological) under active trial.

References

The discovery of GLP-1 and its therapeutic legacy (PNAS review). pnas.org · Lasker citation: laskerfoundation.org
Kobilka, GPCR structure (2012 Nobel lecture / review). Angew. Chem.
Peptide half-life extension — lipidation, albumin binding, PEGylation (review). ACS Med. Chem. Lett.
FDA: proposal to exclude semaglutide/tirzepatide/liraglutide from the 503B bulks list. fda.gov

Explore the full library & 75-compound reference →

For educational and research purposes only. This content is not medical advice. Semaglutide is a prescription drug; obtain and use medicines only under a licensed professional. Free Peptide University does not sell compounds.